Defne comes to Interface Biologics Inc. with both industry and audit experience. Most recently, she worked as Assistant Controller, Latin America, at SAS Institute (Canada) Inc., a subsidiary of one of the largest private technology companies worldwide, where she managed the coordination, consolidation, preparation and analysis of Latin American regional financial management reports for seven Latin American subsidiaries. Prior to SAS, she worked as a Senior Accountant, Consumer Markets, at KPMG LLP. She holds a B.Sc. Honours Biotechnology/Chartered Accountancy degree as well as a Masters of Accounting from the University of Waterloo and is a CPA, CA with the Institute of Chartered Accountants of Ontario.

Jeannette is a charter member of the Interface Biologics scientific team. During her tenure, she has served as Director of Research and Development, Director of Operations and leads the Endexo™ development team. Jeannette was involved in developing Endexo™ technology during her graduate studies at the University of Toronto. She was also President of Jycho Surface Technologies, Inc., the company that began the scale-up and commercialization of the Endexo™ technology. She brings expertise in surface modifying macro-molecule (SMM) technology, biomaterials, polymer science, industrial processing and device manufacturing. Jeannette holds a B.A.Sc. in Chemical Engineering from the University of Waterloo and a M.A.Sc. from the University of Toronto.

Wendy recently joined IBI, bringing a wealth of experience from having worked in both large and small medical device companies. She spent 11 years at Boston Scientific in increasingly senior management and R&D roles in the areas of Interventional Cardiology, Peripheral Interventions, Imaging, Endosurgery, Urology/Women’s health and Neuurovascular. Wendy most recently served for five years as Senior Director, Clinical and Preclinical Sciences at 480 Medical, an early stage drug delivery device company in the cardiovascular space. Wendy received her MSc and PhD from the University of Toronto in Biomaterials. She is the inventor of 27 US patents and author of 12 peer-reviewed publications.

Thomas P. Reeves joined Interface Biologics in November of 2008 as President and Chief Executive Officer. Tom brings a wealth of experience in running different companies in a variety of industries through various stages of growth. Most recently, he was President and COO of Occulogix, Inc. (NASDAQ: OCCX) a medical device company where he was instrumental in their Initial Public Offering raising over $100 million. Prior to OccuLogix, Mr. Reeves was the President of Borderfree, an international e-commerce service provider which was sold to Canada Post in 2004. Mr Reeves has also led Beamscope Canada Inc., Merisel Canada, Merisel Europe, and Merisel’s UK operation. Mr. Reeves started his career with the Boston Consulting Group (BCG) in San Francisco. He holds a BA in Economics, magna cum laude, from Harvard University and an MA in International Relations from the Australian National University.

Tom Reeves - EY Entrepreneur Of The Year 2014 Finalist

Dr. Santerre founded Interface Biologics Inc. in 2001 to develop improved medical implants based on his innovative research in polymer chemistry. Dr. Santerre is responsible for the strategic direction of research and development at Interface. Previously, Dr. Santerre was the manager of the materials development laboratory at the University of Ottawa and developed technology for the Ottawa Heart Institute artificial heart (World Heart Corporation). He is currently a full professor of biomaterials with appointments at the Faculty of Dentistry and the Institute for Biomaterials and Biomedical Engineering at the University of Toronto. He is an expert in the areas of physical, surface and biological characterization of polymers, polymer synthesis, material biocompatibility, drug polymers, and medical device manufacturing.

Dr. Paul Santerre, PhD wins the 2014 Ernest C. Manning $100,000 Principal Award

The Endexo Story from Angiodynamics

Frank Shannon re-joined Interface Biologics in May 2016, bringing more than 20 years of experience in clinical development, regulatory affairs and quality assurance in the pharmaceutical and medical device industries. He has led the design, execution, analysis, and reporting of numerous clinical trials and outcomes research studies with industry, government and NGO sponsors.

Frank has worked for large and medium pharmaceutical companies including Ciba-Geigy, Genentech, Roche and Boehringer Ingelheim where he led Medical Affairs for cardiovascular and cerebrovascular disease areas in Canada, including late phase clinical development projects, globally. Subsequently, he moved to the medical device sector, joining Occulogix as the Director of Clinical and Outcomes Research. More recently, he held executive positions in Regulatory Affairs and Quality Assurance at St. Jude Medical and Baxter Corporation, in Canada, prior to rejoining Interface Biologics in 2016. Following his bachelor’s degree in Psychology (Neurosciences) at Brock University, Frank undertook graduate studies in Epidemiology at the University of Toronto and the Institute for Clinical Evaluative Sciences.

Mark coordinated the formation of the company in December 2001. He negotiated licensing terms with the University of Toronto, prepared the terms of the seed capital funding, and organized the company for operations beginning in January 2002. Mark is responsible for managing the financing and business aspects of the corporation. He raised $12M in seed capital for the corporation. He has taken the staff of Interface from 0 to 15 people and helped recruit the senior management team. Mr. Steedman was instrumental in landing early deals with several large medical device manufacturers, and oversaw company operations from early R&D to its first revenues in 2004. Mark holds degrees in Applied Science in Engineering, a Bachelor of Arts in Biology both from Queen’s University and an MBA from Wilfrid Laurier University.